Literature DB >> 15837949

Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone.

Alison Harte1, Philip McTernan, Rajkumar Chetty, Simon Coppack, Jonathan Katz, Stephen Smith, Sudhesh Kumar.   

Abstract

BACKGROUND: Obesity-associated hypertension is likely to be due to multiple mechanisms. Identification of the renin-angiotensin system (RAS) within adipose tissue does, however, suggest a potential causal role for it in obesity-associated hypertension. Obese patients are often hyperinsulinemic, but mechanisms underlying insulin upregulation of the RAS in adipose tissue are unclear. Tumor necrosis factor-alpha (TNF-alpha), an inducer of angiotensinogen in hepatocytes, is elevated in hyperinsulinemic, obese individuals and may provide a link in mediating insulin upregulation of the RAS in adipose tissue. Furthermore, thiazolidinediones lower blood pressure in vivo, and downregulation of the RAS in adipose tissue may contribute to this effect. We therefore examined the effect of rosiglitazone (RSG) on the insulin-mediated upregulation of the RAS. METHODS AND
RESULTS: Sera were obtained from the arterial circulation and from venous blood by draining subcutaneous abdominal adipose tissue. Isolated human abdominal subcutaneous adipocytes (n=12) were treated with insulin (1 to 1000 nmol/L), insulin in combination with RSG (10 nmol/L), and RSG (10 nmol/L) alone to determine angiotensinogen expression and angiotensin II, bradykinin, and TNF-alpha secretion. Subcutaneous adipocytes were also treated with TNF-alpha (10 to 100 ng/mL) to examine the direct effect on angiotensinogen expression and angiotensin II secretion. The findings showed that the arteriovenous difference in angiotensin II levels was significant (>23%; P<0.001). Insulin increased TNF-alpha secretion in a concentration-dependent manner (P<0.01), whereas RSG (10 nmol/L) significantly reduced the insulin-mediated rise in TNF-alpha (P<0.001), as well as angiotensin and angiotensin II. TNF-alpha also increased angiotensinogen and angiotensin II in isolated adipocytes.
CONCLUSIONS: The present in vivo data suggest that human subcutaneous adipose tissue is a significant source of angiotensin II. This study also demonstrates a potential TNF-alpha-mediated mechanism through which insulin may stimulate the RAS and may contribute to explain obesity-associated hypertension. RSG downregulates the RAS in subcutaneous adipose tissue, and this effect may contribute to the long-term effect of RSG on blood pressure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837949     DOI: 10.1161/01.CIR.0000161954.17870.5D

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

Review 1.  Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.

Authors:  Emaad M Abdel-Rahman; Lawand Saadulla; W Brian Reeves; Alaa S Awad
Journal:  J Gen Intern Med       Date:  2011-10-18       Impact factor: 5.128

2.  Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans.

Authors:  G H Goossens; S E McQuaid; A L Dennis; M A van Baak; E E Blaak; K N Frayn; W H M Saris; F Karpe
Journal:  J Physiol       Date:  2006-01-05       Impact factor: 5.182

3.  Regulated renin release from 3T3-L1 adipocytes.

Authors:  Jason D Fowler; Nathan D Johnson; Thomas A Haroldson; Joy A Brintnall; Julio E Herrera; Stephen A Katz; David A Bernlohr
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-03-17       Impact factor: 4.310

4.  Insulin resistance and risk of incident hypertension among men.

Authors:  Tai-Shuan Lai; Gary C Curhan; John P Forman
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-09       Impact factor: 3.738

5.  Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Linda Fried; Ping Tepper; Emma Barinas-Mitchell; Molly B Conroy; Rhobert W Evans; Maria Mori Brooks; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Hypertens Res       Date:  2013-05-09       Impact factor: 3.872

Review 6.  PPARγ and chronic kidney disease.

Authors:  Agnes B Fogo
Journal:  Pediatr Nephrol       Date:  2010-07-30       Impact factor: 3.714

7.  Prenatal exposure to interleukin-6 results in hypertension and alterations in the renin-angiotensin system of the rat.

Authors:  Anne-Maj Samuelsson; Camilla Alexanderson; Johan Mölne; Börje Haraldsson; Peter Hansell; Agneta Holmäng
Journal:  J Physiol       Date:  2006-07-06       Impact factor: 5.182

8.  Rosiglitazone and imidapril alone or in combination alleviate muscle and adipose depletion in a murine cancer cachexia model.

Authors:  Si-Zeng Chen; Jian-Dong Xiao
Journal:  Tumour Biol       Date:  2014-01

9.  Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.

Authors:  Akizuki Morikawa; Kanaki Ishizeki; Yasunori Iwashima; Hiroki Yokoyama; Eiji Muto; Eiji Oshima; Masatomo Sekiguchi; Takanori Miura; Hiroshi Itoh; Masakazu Haneda
Journal:  Clin Exp Nephrol       Date:  2011-08-09       Impact factor: 2.801

Review 10.  Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications.

Authors:  Mi-Jeong Lee; Yuanyuan Wu; Susan K Fried
Journal:  Mol Aspects Med       Date:  2012-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.